Mostrar el registro sencillo del ítem

dc.contributor.authorMishra, Pooja
dc.contributor.authorPawar, Rajendra-Prasad
dc.contributor.authorBose, Devasish
dc.contributor.authorDurgbanshi, Abhilasha
dc.contributor.authorAlbiol Chiva, Jaume
dc.contributor.authorVives-Peris, Vicente
dc.contributor.authorEsteve-Romero, Josep
dc.contributor.authorJain, Abhishek
dc.date.accessioned2019-07-24T09:22:39Z
dc.date.available2019-07-24T09:22:39Z
dc.date.issued2019
dc.identifier.citationMISHRA, Pooja, et al. Stability studies of rifampicin in plasma and urine of tuberculosis patients according to the European Medicines Agency Guidelines. Bioanalysis, 2019, vol. 11, no 08, p. 713-726ca_CA
dc.identifier.issn1757-6180
dc.identifier.issn1757-6199
dc.identifier.urihttp://hdl.handle.net/10234/183375
dc.description.abstractAim: The macrolide antibiotic rifampicin is prescribed against several infections, like tuberculosis disease. This drug decays to rifampicin quinone. Results/methodology: The biological fluids were diluted in a micellar solution and directly injected. Using a C18 column and a mobile phase of 0.15 M SDS-6% 1-pentanol phosphate-buffered at pH 7, running at 1 ml/min, the analytes were resolved in less than 15 min. The detection was by absorbance at 337 nm. Method was validated by the guidelines of the European Medicines Agency. Decomposition of rifampicin to rifampicin quinone was also studied. Discussion/conclusion: Procedure is rapid, easy-to-handle, economic, eco-friendly and with a high sample throughput. It was successfully used to monitor rifampicin in the plasma and urine of tubercular patients.ca_CA
dc.format.extent14 p.ca_CA
dc.language.isoengca_CA
dc.publisherFuture Scienceca_CA
dc.relation.isPartOfBioanalysis, 2019, vol. 11, no 8ca_CA
dc.rights© Future Science Groupca_CA
dc.rights.urihttp://rightsstatements.org/vocab/InC/1.0/*
dc.subjectplasma and urine samplesca_CA
dc.subjectrifampicinca_CA
dc.subjectstability studiesca_CA
dc.subjecttuberculosisca_CA
dc.subjectvalidationca_CA
dc.titleStability studies of rifampicin in plasma and urine of tuberculosis patients according to the European Medicines Agency Guidelinesca_CA
dc.typeinfo:eu-repo/semantics/articleca_CA
dc.identifier.doihttps://doi.org/10.4155/bio-2018-0174
dc.rights.accessRightsinfo:eu-repo/semantics/restrictedAccessca_CA
dc.relation.publisherVersionhttps://www.future-science.com/doi/abs/10.4155/bio-2018-0174ca_CA
dc.type.versioninfo:eu-repo/semantics/publishedVersionca_CA


Ficheros en el ítem

FicherosTamañoFormatoVer

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem